SCHEMBL19911490

SCHEMBL19911490

Cc1ccc2nnn(S(=O)(=O)c3ccccc3)c2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.69
CYP2C19 P33261 1/20 0.54
TSHR P16473 3/20 0.49
HSD17B10 Q99714 2/20 0.49
KMT2A Q03164 1/20 0.49
POLB P06746 2/20 0.48
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.45
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 2/20 0.42
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH3A1 P30838 2/20 0.40
NOD1 Q9Y239 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848576 0.88 SLC9A1 (0.69) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19911488 0.85 SLC9A1 (0.54) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19848288 0.84 SLC9A1 (0.65) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19911636 0.82 SLC9A1 (0.68) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19848551 0.82 SLC9A1 (0.68) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL7746353 0.82 SLC9A1 (1.00) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19848204 0.82 SLC9A1 (0.62) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL2491809 0.81 SLC9A1 (1.00) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL29479875 0.81 SLC9A1 (1.00) SLC9A1CYP2C19TSHRHSD17B10KMT2A
SCHEMBL19848206 0.80 SLC9A1 (0.49) SLC9A1CYP2C19TSHRHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 SLC9A1 341/4885CYP2C19 1476/4885TSHR 2034/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SLC9A1 341/4885CYP2C19 1476/4885TSHR 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.